Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol

• Status: Recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate a novel vancomycin intraosseous administration protocol vs a standard IV vancomycin administration protocol for primary total hip arthroplasty patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Methodist Hospital Research Institute; The Methodist Hospital System
• Treatments: Vancomycin

Criteria

Inclusion Criteria:

• Patient is undergoing a primary total hip arthroplasty

• Patient gives informed consent to participate in the study.

• Age Range >18

Exclusion Criteria:

• Previous surgery on the hip (including hip scopes)

• BMI above 35

• Contraindication to receiving vancomycin or cefepime (allergy, medical issue, etc)

• Inability to locate the greater trochanter or administer the IO infusion

• Refusal to participate

• Diabetes

• Immunocompromised or immunosuppressed patients (HIV, Hep C, End stage renal disease, dialysis, transplant, chemo/radiation treatment in last 6 months, medications).